Episode Summary
Executive Summary: Peter Attia interviews Nir Barzilai on aging biology, focusing on metformin as a proof-of-concept anti-aging drug, the TAME trial, insulin resistance as a stress response, and the genetics of longevity. They also discuss centenarian pathways, especially GH/IGF signaling, autophagy, and why aging should be treated as a targetable process rather than isolated diseases.
Main Topics: Metformin as an anti-aging candidate (Priority: 5/5): Barzilai explains why metformin, beyond diabetes care, may slow aging through multiple pathways and why it is the lead drug for the TAME trial. TAME trial and regulatory strategy (Priority: 5/5): The conversation details the design, rationale, funding, and FDA challenges of testing aging as an indication using a composite endpoint of age-related diseases. Insulin resistance and metabolic adaptation (Priority: 5/5): They unpack insulin resistance in muscle, liver, and fat, arguing it can function as a protective stress response rather than a purely pathological state. Centenarian genetics and longevity pathways (Priority: 5/5): Barzilai describes genetic findings in centenarians and their offspring, emphasizing GH/IGF, FOXO3A, CTP, and gene-gene interactions. Growth hormone / IGF and lifespan (Priority: 4/5): The discussion explores why lower IGF signaling may be beneficial in women, the mixed evidence in men, and how receptor-level interventions may extend healthspan. Autophagy, fasting, and nutrient sensing (Priority: 4/5): Attia and Barzilai connect fasting, autophagy, AMPK, and mTOR as overlapping longevity mechanisms and discuss timing effects in humans versus rodents. NAD precursors and evidence standards (Priority: 3/5): They close with skepticism about NR/NMN hype, emphasizing the need for controlled human trials before broad claims about efficacy.
Key Arguments: Metformin is not just a glucose-lowering drug; it may act on aging biology through AMPK, mTOR, mitochondrial effects, inflammation, and epigenetic changes. The TAME trial is designed to prove that aging can be targeted clinically using a composite of age-related outcomes rather than a single disease endpoint. Insulin resistance can be a protective response to nutrient excess, especially in muscle, where glucose uptake capacity is limited. Visceral fat appears to be a major driver of metabolic harm; removing it in animal models improved lifespan and healthspan. Centenarians are not disease-free; they tend to delay chronic disease onset and compress morbidity rather than escape disease entirely. The GH/IGF axis is strongly implicated in human longevity, especially in women, with multiple centenarian-associated mutations affecting this pathway. Many apparent benefits of longevity interventions may be secondary readouts of slowed aging rather than direct primary effects on each biomarker. Claims about NAD boosters remain premature without rigorous human trials, despite promising anecdotes and some biomarker changes.
Data Points: TAME sample size: 3,000 participants - Planned randomized trial of metformin for aging, ages 65-80. TAME sites: 14 centers - Multi-center U.S.-only trial design. TAME allocation: 1:1 - Metformin versus placebo randomization. TAME duration: 5 years - Prospective follow-up for age-related outcomes. TAME dose: 1,500 mg/day - Planned metformin dose in the trial. Metformin mortality reduction: 17% lower mortality - UK observational study of newly prescribed metformin monotherapy versus non-diabetic controls. Metformin effect on diabetes prevention: 30% reduction - Referenced from the Diabetes Prevention Program. Metformin effect on insulin in animals: ~10% - Barzilai contrasted metformin’s modest insulin effect with stronger agents like rapamycin. Rapamycin effect in rodents: ~24% lifespan increase - Used as a comparison for longevity potency. Visceral fat removal benefit in rats: ~20% longer lifespan - Ad libitum-fed rats without visceral fat lived longer than controls. Caloric restriction benefit in rats: ~40% longer lifespan - Benchmark group in the visceral fat experiment. Zucker rat diabetes timing: By 6 months - Obese Zucker rats developed diabetes by six months unless visceral fat was removed. Centenarian IGF finding: Lowest IGF-1 group lived twice as long - Among centenarians, lower IGF-1 was associated with greater longevity in women. IGF receptor mutation prevalence in centenarians: 9 centenarians (~2%) - Functional IGF receptor variants identified as proof of concept. Growth hormone receptor exon 3 deletion prevalence: 12% in centenarians vs 3-4% in controls - Common longevity-associated receptor variant. MicroRNA cluster prevalence: ~30% of centenarians - MicroRNAs targeting IGF signaling were overrepresented. FOXO3A mutation prevalence: ~22% of centenarians - A common longevity-associated transcription factor variant. LPA decline with age: Drops by half until age 80 - Cross-sectional pattern suggesting strong selection against high Lp(a) before old age. CTP VV prevalence: 8% at age 55; 20% at age 100 - Longevity-associated genotype becomes enriched in older ages. IGF receptor antibody study: 10% lifespan increase - Female mice treated at 22 months showed longer lifespan and better healthspan. Human metformin crossover study: 15 people, 6 weeks each arm - Biopsy-based study of muscle and adipose tissue transcriptomics.
Pivotal Quotes: "“Insulin resistance is a protective mechanism. It's a modulator. It's a stress response.”" — Nir Barzilai: Explaining why insulin resistance may promote longevity in some contexts rather than simply causing disease. "“We are not interested in diabetes. We are going to have a cluster and we're just going to delay the aging.”" — Nir Barzilai: Describing the logic behind the TAME trial and its composite endpoint approach. "“Metformin is a tool from my perspective. It's just a tool to show that we can target aging.”" — Nir Barzilai: Clarifying that metformin is a proof-of-principle intervention, not necessarily the final optimal anti-aging drug.
Implications: The episode argues aging is clinically targetable and that metformin is the best current proof-of-concept, but not the endpoint. It also pushes listeners to think in pathways, sex differences, and composite outcomes rather than single biomarkers or diseases.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.